GlassScriptPhysician profile
Robert A Kimelheim
NPI 1508837766
$384,337.38
in general payments reported to CMS, 2019-2025
36 companies · $6,532 in 2025
The $6,532 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171K · 2020: $42K · 2021: $35K · 2022: $55K · 2023: $62K · 2024: $13K · 2025: $6,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $16K · Food and Beverage: $6,989 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,560.00 |
| Travel and Lodging | $15,621.19 |
| Food and Beverage | $6,989.22 |
| Education | $146.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $150,906.31 | 2020-2025 | Acthar |
| Amgen INC. | $82,996.57 | 2019-2025 | Otezla, Tavneos, Evenity |
| Mallinckrodt Enterprises LLC | $57,161.15 | 2019 | |
| Lilly USA, LLC | $49,291.44 | 2019-2024 | Taltz, Olumiant |
| Celgene Corporation | $27,423.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10,077.45 | 2019-2025 | |
| Abbvie INC. | $1,509.46 | 2019-2025 | |
| Janssen Biotech, INC. | $1,035.18 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.36 | 2023-2024 | Ofev, Spevigo |
| Ucb, INC. | $394.09 | 2020-2024 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $373.32 | 2019-2022 | |
| Glaxosmithkline, LLC. | $356.61 | 2019-2023 | Benlysta, Nucala |
| Pfizer INC. | $356.15 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $347.55 | 2021-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $333.18 | 2021-2024 | Orencia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $194.07 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $181.07 | 2023-2025 | Purified Cortrophin Gel |
| Janssen Scientific Affairs, LLC | $178.35 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.21 | 2022 | |
| Genzyme Corporation | $96.92 | 2023-2024 | |
| Sobi, INC | $88.97 | 2020-2021 | |
| Nevro Corp. | $88.56 | 2024 | Senza |
| Genentech USA, INC. | $77.02 | 2020-2025 | Actemra |
| Biofrontera INC. | $51.41 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Regeneron Healthcare Solutions, INC. | $48.65 | 2024 | Libtayo |
| Leo Pharma INC. | $44.89 | 2024 | Adbry |
| Fresenius Kabi USA, LLC | $33.69 | 2024 | Idacio |
| Gilead Sciences, INC. | $29.77 | 2020 | |
| Krystal Biotech INC | $22.71 | 2023 | Vyjuvek |
| Sensus Healthcare, INC. | $22.00 | 2024 | |
| Octapharma USA, INC. | $19.44 | 2024 | Octagam Immune Globulin (Human) |
| Neurocrine Biosciences, INC. | $18.95 | 2025 | |
| Sun Pharmaceutical Industries INC. | $18.08 | 2024 | |
| Blueprint Medicines Corporation | $15.32 | 2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $13.20 | 2024 | |
| Jazz Pharmaceuticals INC. | $12.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kimelheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.